MRI in Lung Cancer Patients
Magnetic Resonance Imaging (MRI) for the Delineation of Organs At Risk (OAR) and Target Volumes in Lung Cancer Patients.
The Christie NHS Foundation Trust
Duration of Study in the UK
1 years, 6 months, 1 days
Lung cancer is associated with a very poor prognosis (<10% survival at 5 years). There is strong evidence that improved local control can increase survival in lung cancer patients and treatment intensification regimens are currently under evaluation. To enable dose escalation with acceptable toxicities we require new imaging techniques allowing more accurate definition of treatment volumes and organs at risk (OARs).
MRI provides greater soft tissue contrast than Computed Tomography (CT) as well as functional information. MRI can aid in the accurate delineation of primary tumour, involved lymph nodes and OARs for lung cancer patients. The addition of an MRI planning scan could lead to more accurate planning volumes and improved overall survival rates.
In this work, 26 lung cancer patients who are attending for radical radiotherapy treatment will be invited for two MRI scans. The aim is to compare OAR and target volume delineation across multiple observers allowing inter and intra observer variation to be assessed. CT, Positron Emission Tomography (PET) and cone-beam CT (CBCT) scans, which are standard of care, will also be included in the study to determine whether MRI significantly changes how clinicians contour the target, lymph nodes and OARs.
North West - Greater Manchester Central Research Ethics Committee
Date of REC Opinion
22 Jun 2017